Caracterización clínica y evaluación de la respuesta terapéutica del linfoma No Hodgkin de Inmuno feno tipo B

Abstract

Abstract: Non-Hodgkin's lymphoma (NHL), a diverse group of hematological neoplasms, consists of the neoplastic proliferation of a malignant cell originating from a B or T lymphocyte affecting the lymph nodes or the extraglanglionic lymphoid system. Objective: Describe the clinical manifestations and therapeutic response of Immunophenotype B Non-Hodgkin's Lymphoma. Methodology: A bibliographic review of publications from 2014 in databases such as PubMed and Google Scholar was carried out, using the medical search term"MeSH". Results: Of the total of 140 articles retained, 16 studies were analyzed. In which NHL predominance is demonstrated in males, aged 53 to 55 years, Non-Hodgkin's Lymphoma of immunophenotype B is the most common and the histological subtype is Diffuse Large B-cell Lymphoma. Conclusions: In the clinical picture, there is a greater frequency of B symptoms, cervical lymphadenopathy, and extraglanglionic involvement occurs more frequently in the gastrointestinal system. The therapy associated with Rituximab is considered a first-line treatment for the various histological subtypes of NHL immunophenotype B.